● TIER 3 — Information onlyGRADE B (negative)Nootropic / neuro peptides
Cerebrolysin
Porcine brain peptide mixture. Research verification: Yes (TGA pending). Origin: Austria (EVER Pharma); heavy use in Russia, E. Europe, China, Asia. Citations verified: yes. 6 human study record(s) in the FitClinicMD studies database.
GOALS · Cognition
FDA status
Not approved in US.
Compounding (503A/503B)
Not compoundable.
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
Neurotrophic mixture. (East) Porcine-brain-derived mixture of low-molecular-weight peptides and amino acids; proposed neurotrophic action.
Human evidence · 6
no mortality benefit; probably more non-fatal SAEs. Cerebrolysin for acute ischaemic stroke.
Cochrane 2023 update.
2023systematic reviewn=1601
Ziganshina LE et al. Cochrane 2020 (PMID 32662068).
Cui S et al. Cochrane 2019, CD008900.pub3.
2019systematic reviewn=597
Muresanu DF et al. CARS. Stroke 2016.
Heiss WD et al. CASTA. Stroke 2012;43:630-6 (NCT00868283).
Reference only. This page summarizes publicly available regulatory and research information about Cerebrolysin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.